Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$0.31 - $1.5 $4,760 - $23,034
15,356 New
15,356 $4,000
Q1 2022

May 17, 2022

SELL
$1.33 - $2.59 $52,774 - $102,771
-39,680 Closed
0 $0
Q4 2021

Feb 15, 2022

BUY
$2.0 - $3.65 $79,360 - $144,832
39,680 New
39,680 $92,000

Others Institutions Holding ARDS

About Aridis Pharmaceuticals, Inc.


  • Ticker ARDS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,701,600
  • Description
  • Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...
More about ARDS
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.